Insider Buying: OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Buys $247,668.75 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton purchased 78,625 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were bought at an average price of $3.15 per share, for a total transaction of $247,668.75. Following the completion of the transaction, the chief executive officer now directly owns 1,259,664 shares in the company, valued at $3,967,941.60. This represents a 6.66 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

OraSure Technologies Stock Up 11.2 %

Shares of OraSure Technologies stock opened at $3.48 on Friday. The business has a fifty day simple moving average of $3.78 and a 200-day simple moving average of $4.00. The firm has a market cap of $259.59 million, a price-to-earnings ratio of 23.20 and a beta of 0.05. OraSure Technologies, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $7.81.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, February 22nd.

Institutional Investors Weigh In On OraSure Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its holdings in shares of OraSure Technologies by 202.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 5,234 shares in the last quarter. Causeway Capital Management LLC acquired a new position in OraSure Technologies in the fourth quarter worth approximately $36,000. Raymond James Financial Inc. acquired a new position in OraSure Technologies in the fourth quarter worth approximately $37,000. Boothbay Fund Management LLC bought a new position in shares of OraSure Technologies in the fourth quarter valued at $42,000. Finally, Gotham Asset Management LLC acquired a new stake in shares of OraSure Technologies during the 4th quarter valued at $43,000. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.